Arbutus Biopharma (ABUS) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.
- Arbutus Biopharma's Income towards Parent Company rose 6080.52% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 4489.46%. This contributed to the annual value of -$69.9 million for FY2024, which is 402.06% up from last year.
- Latest data reveals that Arbutus Biopharma reported Income towards Parent Company of -$7.7 million as of Q3 2025, which was up 6080.52% from $2.5 million recorded in Q2 2025.
- Arbutus Biopharma's 5-year Income towards Parent Company high stood at $2.5 million for Q2 2025, and its period low was -$24.5 million during Q1 2025.
- In the last 5 years, Arbutus Biopharma's Income towards Parent Company had a median value of -$17.9 million in 2024 and averaged -$16.7 million.
- Per our database at Business Quant, Arbutus Biopharma's Income towards Parent Company plummeted by 3762.33% in 2021 and then skyrocketed by 11264.4% in 2025.
- Arbutus Biopharma's Income towards Parent Company (Quarter) stood at -$21.3 million in 2021, then decreased by 2.87% to -$21.9 million in 2022, then increased by 11.95% to -$19.3 million in 2023, then surged by 35.28% to -$12.5 million in 2024, then skyrocketed by 38.16% to -$7.7 million in 2025.
- Its last three reported values are -$7.7 million in Q3 2025, $2.5 million for Q2 2025, and -$24.5 million during Q1 2025.